Gastrointestinal Neuroendocrine Tumors by Ozcan Yildiz & Suheyla Serdengecti
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
5 
Gastrointestinal Neuroendocrine Tumors 
Ozcan Yildiz and Suheyla Serdengecti  
Istanbul University/Cerrahpasa Medical Faculty,Department of Internal Medicine, 
Division of Medical Oncology Istanbul, 
Turkey 
1. Introduction 
Gastrointestinal carcinoid tumors date back to 1888 when Otto Lubarsch found multiple 
tumors in the distal ileum of two patients at autopsy (Lubarsch, 1888). The German pathologist 
Siegfried Oberndorfer was the first who used the term “Karzinoide Tumoren”, the English 
translation of which is “carcinoid tumor”. He coined this term because these tumors behaved 
less aggressively than true carcinomas (Oberndorfer, 1907). Oberndorfer contributed to the 
Department of Pathology of Istanbul University where he remained full professor and director 
until his death in 1944 (Dogan & Hot, 2010; Klöppel et al., 2007). In 1914, Gosset and Masson 
first mentioned neuroendocrine features of carcinoid tumors. In 1954, Thorson and co-workers 
described the term "carcinoid syndrome" after they found that the tumors contained serotonin 
and patients with small intestinal carcinoid tumor and liver metastases presented with the 
characteristic symptoms of diarrhea, flushing, asthma, and right heart failure (Thorson et al., 
1954). It was soon recognized as a distinct entity after they were reported in several organs 
belonging to bronchopulmonary system and gastrointestinal tract (Yalcin, 2006). Although 
better named as “neuroendocrine tumors” after the WHO meeting in 2000, these tumors have 
been traditionally called “carcinoids” especially at some specific locations such as the 
gastrointestinal tract. Therefore, the terms “carcinoid tumor” and “neuroendocrine tumor” are 
used interchangeably throughout the text. 
2. Epidemiology 
Although it might not reflect the true incidence due to their indolent nature, the overall 
incidence of carcinoid tumors in the United.States has been estimated to be 1 to 2 cases per 
100,000 people (Godwin, 1975; Modlin & Sandor, 1997). Yao and co-workers reviewed 
35,825 neuroendocrine tumors (NETs) compiled from 1973 to 2004 (Yao et al., 2008). 
According to this review, 41% was foregut NETs, 26% midgut NETs, and 19% hindgut 
NETs. In the remaining 13%, the primary tumor site was unknown or could not be 
classified. These figures were similar to our institution’s patient cohort (Yildiz et al., 2009). 
In Sweden, combined with the autopsy series the incidence has been calculated to be 8.4 
cases per 100,000 people. Based on the data from the End Results Group (1950-1969) and the 
Third National Cancer Survey (1969-1971) the most common site of carcinoid tumors was 
appendix followed by the rectum, ileum, lung and bronchi, and stomach (Godwin, 1975). 
Pancreatic endocrine tumors are relatively less frequent and account for 2% of malignant 
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tumors of the gastrointestinal tract. Recent data obtained from the National Cancer Institute 
Surveillance, Epidemiology, and End Results program (1973 to 1997) showed that, of the 
11,427 cases analyzed, the overall incidence rates for carcinoid tumors have increased 
significantly over the past 25 years, although rates for some sites have decreased (e.g., 
appendix). The gastrointestinal tract accounted for 54.5% of the tumors. Within the 
gastrointestinal tract, the small intestine was the most common site (44.7%), followed by the 
rectum (19.6%), appendix (16.7%), colon (10.6%), and stomach (7.2%). The average age was 
60.9 years, and 54.2% were female. The 5-year survival rates for the most common 
gastrointestinal sites were 75.1% for stomach, 76.1% for small intestine, 76.3% for appendix, 
and 87.5% for rectum (Maggard et al., 2004). 
3. Pathology and classification 
Carcinoid tumors are thought to arise primarily from the neuroendocrine cells of the lung 
and the gastrointestinal tract. In the past, these cells were called "Kulchitsky cells" or 
"enterochromaffin cells" due to the affinity for soluble silver salts, hence the term 
argentaffinomas. Although not prognostically useful, historically, carcinoid tumors have 
been classified according to their embryologic derivation within the primitive gut (Williams 
& Sandler, 1963): Foregut, midgut, and hindgut carcinoids. Foregut carcinoids include 
intrathoracic (thymic and bronchial), gastric, esophageal, upper duodenal, and pancreatic 
carcinoids. They usually produce low levels of serotonin, 5-hydroxytryptophan (5-HTP), 
histamine, or adrenocorticotropic hormone. Midgut carcinoids include carcinoids of distal 
duodenum, jejunum, ileum, appendix, proximal colon, liver, ovary, or testes. These tumors 
have the propensity of producing serotonin at high levels. Finally, hindgut carcinoids 
include carcinoids of distal colon and rectum. They less likely produce serotonin but may 
produce somatostatin, peptide YY, 5-HTP, or other hormones (Table 1). 
Useful immunohistochemical markers in modern pathology include neuron-specific enolase 
(NSE), synapthophysin and chromogranin A (CgA) which is also a secretory product of the 
carcinoid cells used to monitor disease activity (Table 2). On gross examination, carcinoid 
tumors are small yellow nodules located submucosally. When they invade the serosa, an 
intense desmoplastic reaction occurs that may lead to intestinal kinking and obstruction. 
The WHO 1980 classification had taken into account the histologic features apart from the 
site of origin (Bosman et al., 2010; table 3). According to this revised system, well-
differentiated neuroendocrine tumors are typical tumors that show characteristic growth 
pattern and benign behavior. They are indolent tumors, confined to mucosa or submucosa, 
and less than 1 to 2 cm in diameter.  
In the WHO 2000 classification, features such as differentiation and proliferation were 
retained, but location, tumor size, tumor extent, and angioinvasion were transferred into the 
TNM (Tumor, Node, Metastasis) staging classification. The WHO 2010 classification states 
that all GEP-NETs are potentially malignant, but differ in their ability of metastasis (Rindi et 
al., 2010). Well-differentiated NETs are classified together as neuroendocrine tumors (NETs) 
G1 or G2. NET G1 is analogous with carcinoid. The term neuroendocrine carcinoma (NEC), 
unlike NET, refers to all poorly differentiated NETs. NEC is further subdivided into a small-
cell and a large-cell variant. In respect of proliferation, all NECs are actively proliferating G3 
tumors. Mixed adenoneuroendocrine carcinomas (MANEC) and hyperplastic and 
preneoplastic lesions are special groups. This classification is complemented by GEP-NET-
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specific TNM classifications and a grading system, which improves prognostic and 
treatment stratification (Schott et al., 2011).  
 
Secretory products of carcinoid tumors Frequency (%) 
Amines  
5-Hydroxytrypta mine - 
5-Hydroxyindoleacetic acid 88 
5-Hydroxytryptophan - 
5-Hydroxyindoleacetaldehyde - 
Histamine - 
Dopamine - 
Tachykinins - 
Kallikrein - 
Substance P 32 
Neuropeptide K 66 
Peptides  
Pancreatic polypeptide 43 
Chromogranins 100 
Neurotensin 41 
Human chorionic gonadotrophin-alpha 28 
Human chorionic gonadotropin-beta 12 
Motilin  14 
Pancreastatin  - 
Other  
Prostaglandins - 
(O’Dorisio, 2011; Vinik et al., 2008; Norheim et al., 1987; Feldmann & O’Dorisio 1986; Eriksson et al., 1990) 
Table 1. Secretory products and known frequency of carcinoid tumors 
 
Foregut Midgut Hindgut
Argyrophilic Argentaf:fin-positive Argyrophilic
CgA-positive CgA-positive CgA-positive 
NSE-positive NSE-positive NSE-positive 
Synaptophysin-positive Synaptophysin-positive Synaptophysin-positive 
  SVP-2-positive 
CgA: Chromogranin A; SVP-2: Seminal vesicle protein-2; NSE: neuron specific enolase 
Table 2. Immunestaining of carcinoid tumors regarding their embryonic origin 
Well-differentiated endocrine tumors may exhibit uncertain behavior. They may be 
angioinvasive. They may also produce serotonin and enteroglucagon. Another subset is 
well-differentiated endocrine carcinomas once termed "atypical" or "anaplastic". They are 
subdivided into low-grade and high-grade malignant carcinoids. Low-grade malignant 
carcinoids are deeply invasive (muscularis propria or beyond) and serotonin-producing 
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when metastatic disease develops. High-grade malignant carcinoids, on the other hand, are 
small to intermediate carcinomas. Appendiceal and rectal carcinoids are rarely malignant, 
whereas ileal, type III gastric, and colonic ones are frequently malignant. Size is also a 
predictor of the malignant potential of the carcinoid tumor. More than 66% of carcinoids 
greater than 2 cm exhibit distant spread when first diagnosed (Capella et al., 1995). 
WHO 1980 
I. Carcinoid 
WHO 2000 
1. Well-differentiated 
differentiated 
endocrine tumor 
(WDET) 
2. Well-differentiated 
endocrine 
carcinoma (WDEC)
3. Poorly 
differentiated 
(small-cell) 
endocrine 
carcinoma (PDEC) 
WHO 2010 
1. Neuroendocrine tumor 
G1 (Carcinoid) 
 
 
2. NET G2 
 
 
3. Small or large-cell 
neuroendocrine 
carcinoma G3 (NEC) 
 
II.  Mucocarcinoid  
III.  Mixed carcinoid-
adenocarcinoma 
4. Mixed endocrine-
exocrine carcinoma 
(MEEC) 
5. Mixed 
adenoneuroendocrine 
carcinoma 
IV. Pseudotumorous 
lesion 
6. Tumor-like lesions 
(TLL) 
7. Hyperplastic and 
preneoplastic lesion 
Table 3. Comparison of the WHO classifications of gastroenteropancreatic neuroendocrine 
tumors. Bosman FT, et al., WHO classification of tumors of the digestive system. Lyon, 
France: IARC Press; 2010. 
4. Clinical chemistry 
Clinically functioning carcinoid tumors produce typical syndromes according to the specific 
circulating peptide. One of the best-characterized of these peptides is serotonin (5-HT). It is 
synthesized from 5-hydroxytryptophan (5-HTP) and metabolized to 5-hydroxyindoleacetic 
acid (5-HIAA) which is excreted in the urine. Measurement of 5-HIAA in the urine is an 
important tumor marker in the carcinoid syndrome, especially in midgut carcinoids. 
Recently, measurements of serotonin in platelets have been recommended for the detection 
of carcinoid tumors that secrete only small amounts of serotonin and/or its precursor 5-
hydroxytryptophan (Kema et al., 2000). Tumors originating from foregut carcinoids (lung, 
pancreas, and stomach) may have relatively low levels of 5-HTP decarboxylase. 5-HTP, 5-
HT, and 5-HIAA are excreted in the urine. 
5. Clinical features of individual carcinoids 
5.1 Foregut carcinoids 
For the sake of completeness we will discuss thymic and pulmonary carcinoids in the 
following sections. 
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5.1.1 Thymic carcinoids 
Thymic carcinoids are rare and may be part of multiple endocrine neoplasia type 1 (MEN1). 
The tumor is usually non-functioning and occurs as an anterior mediastinal mass. The mass 
may be partly calcified and may cause superior vena cava obstruction. Extension into the 
pleura, pericardium, great vessels, or regional lymph nodes is commonly seen. Functioning 
thymic carcinoids usually secrete adrenocorticotrophic hormone (ACTH), which may lead 
to Cushing's syndrome. In these cases bilateral adrenal hyperplasia may also be seen. Other 
hormones include corticotrophin-releasing hormone, growth hormone-releasing hormone 
(GHRH) and 5-HT. Carcinoid syndrome has been described with a multidirectional 
carcinoma of the thymus with neuroendocrine and sarcomatous components. (Paties et al., 
1991) 
5.1.2 Pulmonary carcinoids 
Pulmonary carcinoid tumors comprise about 2% of primary lung tumors. They are believed 
to arise from neuroendocrine Kulchitsky's cells of the proximal bronchial mucosa, and 
bronchopulmonary tract is the second common site of carcinoid tumors after the 
gastrointestinal system. They have been classified into three groups, according to their 
malignant potential: Benign or classical bronchial carcinoid, low-grade malignant or atypical 
carcinoid, and high-grade malignant or poorly differentiated carcinoma of the large cell or 
small cell type. 
Neuroendocrine tumors of the lung can also be divided into 5 groups: Tumorlet, diffuse 
idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) (Nassar et al., 2011), 
carcinoid tumor, atypical carcinoid tumor, and small cell carcinoma of the lung. Typical 
carcinoids of the lung present in the fifth decade of life and are more common in females. 
These tumors are not related to smoking. Neuroendocrine manifestations are relatively 
uncommon. Common symptoms  are  cough, hemoptysis, wheezing, and chest pain (Table 
4). Recurrent pneumonia can occur due to obstructing lesions. Cushing's syndrome and 
acromegaly may be seen due to the secretion of ACTH and GHRH, respectively. The 
prognosis is excellent for classical bronchial carcinoids. Diagnostic tools for pulmonary 
carcinoids are generally non-specific. Bronchoscopic biopsy should be used to obtain 
diagnostic tissue, despite the feared complication of hemorrhage. 
 
Carcinoid tumors Clinical features
Foregut 
Bronchial carcinoids  
Gastric carcinoids 
 
Cough, hemoptysis, wheezing, chest pain, pneumonia  
Usually found incidentally 
Midgut  
Small intestinal carcinoids 
Appendiceal carcinoids 
 
Bowel obstruction 
Nonspecific abdominal pain, carcinoid syndrome 
Usually found incidentally 
Hindgut  
Rectal carcinoids 
 
Bleeding, pain, constipation, carcinoid syndrome 
Table 4. Clinical features of neuroendocrine tumors 
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Treatment should not be radical unless there is lymph node metastasis. Options include 
lobectomy, segmentectomy, and bronchotomy with tumor enucleation. Curative or 
palliative metastasectomies are worth trying since they grow slowly. Carcinoid crisis should 
be prevented with octreotide administration preoperatively. When chemotherapy is 
indicated in some patients, 5-fluorouracil and streptozotosin or cisplatin and etoposide are 
most commonly used regimens. Other drugs used in metastatic pulmonary carcinoids are 
octreotide, 131I-MIBG, and interferon alpha. Stage-by-stage, the outcome is worse for 
patients with atypical carcinoids than for those with typical carcinoids (Kaplan et al., 2003). 
5.1.3 Gastric carcinoids 
Gastric carcinoids are rare neoplasms of the stomach comprising less than 1% of gastric 
tumors and 8.7% of all gastrointestinal neuroendocrine tumors (Godwin, 1975; Modlin et al., 
1997) (Table 4). The incidence is reported to be 1.2 and 1.8/1,000,000 persons/year in white 
males and females, respectively. Three types have been described: Those associated with 
chronic atrophic gastritis type A (CAG-A or type I), those associated with Zollinger-Ellison 
syndrome (type II), and sporadic gastric carcinoid tumors (type III). The first 2 groups of 
carcinoids are associated with hypergastrinemia. CAG-A associated carcinoids are the most 
common type (70-80% of cases). The typical patient is a woman in her sixties with 
pernicious anemia, hypochlorhydria, and hypergastrinemia. High levels of gastrin may 
mediate the hyperplasia of enterochromaffin-like (ECL) cells in the gastric mucosa and 
ultimately, carcinoid tumors may develop. They are small indolent, non-functioning tumors 
and located multifocally in the body or fundus, which are diagnosed incidentally (Rindi et 
al., 1993; Gough et al., 1994; Moses et al., 1986). Tumors less than 1 cm have been 
successfully resected and followed endoscopically (Ahlman et al., 1994; Sjoblom et al., 1993). 
Gastric carcinoids associated with the Zollinger-Ellison syndrome (ZES) almost always 
occur in patients with multiple endocrine neoplasia type 1 (MEN1 or Wermer’s syndrome) 
suggesting a genetic predisposition. Five percent of gastric carcinoids are of type II. The 
treatment and prognosis are similar to those of CAG-A associated carcinoids. Within this 
group, there is also a non-MEN1 associated sporadic ZES which rarely leads to gastric 
carcinoid tumor development. Interestingly, 99% of them had ECL hyperplasia and 
abnormal alpha-human chorionic gonadotropin (a-hCG) staining. Sporadic gastric 
carcinoids (type III), in contrast, are not associated with hypergastrinemia and follow an 
aggressive clinical course. In addition to being solitary, they are usually more than 1 cm in 
size and often metastatic at the time of diagnosis. When feasible, radical gastrectomy is the 
treatment of choice. 
5.2 Midgut carcinoids 
5.2.1 Small intestinal carcinoids 
Small bowel is not only the most frequent site of carcinoid tumors (including metastatic 
carcinoids), but also carcinoids are the commonest primary malignant tumor of the distal 
small intestine. Their frequency has recently surpassed adenocarcinoma (44% versus 33%) 
(Bilimoria et al., 2009). More than one third of the small bowel tumors are diagnosed as 
carcinoids and of all gastrointestinal carcinoids; 42% arise in the small bowel of which the 
ileum represents the most common localization followed by the duodenum and the 
jejunum. The annual incidence rate is 0,28 per 100,000. Patients usually present in 6th or 7th 
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decade of life with mechanical obstruction or vague abdominal pain, sometimes for several 
years before the diagnosis perhaps due to their submucosal location. These tumors are 
thought to originate from serotonin-producing intraepithelial endocrine cells and they tend 
to have high serotonin content. They are multicentric and the most frequent location is the 
distal ileum. Lymph node and liver metastasis are common but carcinoid syndrome is seen 
only in 5 to 7% of the patients (Burke et al., 1997; Bilimoria et al., 2009). Metastases tend to 
occur in liver, bone and lung. Unlike appendiceal carcinoids, smaller tumors have also been 
found to have metastasized. Nevertheless, tumors measuring 2 cm in diameter have almost 
always been proved to have distant spreading. 
Based on patients, registered in the Swedish Cancer Registry, with small intestinal 
carcinoids diagnosed from 1960 to 2000 in the duodenum (n= 89) and jejunum/ileum 
(n=2437), the overall 5-, 10-, and 15 year survivals were, respectively, 60, 46, and 28% for 
duodenal tumors and 56, 36, and 23% for jejunal/ileal tumors (Zar et al., 2004). 
5.2.2 Appendiceal carcinoids 
Carcinoid tumors are the most common cancers of the appendix (Moertel et al., 1968) 
originating from subepithelial endocrine cells (Lundqvist & Wilander, 1986; Shaw, 1990). 
They are detected most commonly after appendectomy performed for other reasons and 
they are found in 0.3-0.9% of patients undergoing appendectomy (Goede et al., 2003). 
Median age is 4th or 5th decade of life (Modlin & Sandor, 1997). This age range is partly 
explained by higher appendectomy rate in young adults. Less than 10% of appendiceal 
carcinoids cause symptoms due to the distal localization of the tumor (Moertel et al., 1987). 
However, they become symptomatic earlier than the carcinoids of other sites. This may also 
explain the relatively less frequent metastasis of appendiceal carcinoids regarding tumor 
size. On the other hand, the size of the tumor is the best predictor of outcome according to 
the Mayo Clinic series. The critical size has been found to be 2 cm. Therefore, right 
hemicolectomy is the treatment of choice for those tumors that are more than 2 cm in size as 
well as those located at the base of the appendix regardless of their size. Local desmoplasia 
is another indication of right hemicolectomy. Otherwise simple appendectomy suffices as 
there is no evidence of recurrence after a median follow-up of more than 25 years in the 
appropriate age group (Moertel et al., 1987). 
5.3 Hindgut carcinoids 
5.3.1 Colonic carcinoids 
Less than 1% of colon cancers are carcinoids (Modlin IM, 1997). The usual presentation of 
colonic carcinoids in patients is bleeding, pain and obstruction (Table 3). In a study of 72 
patients, the more common symptoms were pain, anorexia and weight loss (Rosenberg JM, 
1985). Patients were usually at their 7th decade of life. The most common location was 
cecum. Midgut colonic carcinoids, namely proximal colonic ones, are believed to arise from 
serotonin-secreting epithelial endocrine cells, behave more aggressively and symptomatic 
tumors need to be approached radically. Fulguration should be avoided in colonic 
carcinoids due to a risk of perforation. As for prognosis, 5-year survival rate is 70% in 
patients with local disease; 44% and 20% in patients with regional metastases and distant 
spread, respectively. 
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5.3.2 Rectal carcinoids 
Rectal carcinoids constitute 1 to 2% of all rectal cancers and are the most common hindgut 
carcinoid. They occur most commonly in the 6th decade of life (Modlin & Sandor, 1997). 
Recent series have shown that they are relatively common (Matsui et al., 1993; Jemore et al., 
1992). In one series between 1992 and 1999, they accounted for 27% of all gastrointestinal 
carcinoid tumors (Modlin et al., 2003). Unlike other carcinoids, they do not usually produce 
serotonin and therefore do not cause carcinoid syndrome despite extensive metastases. 
Symptomatic patients have rectal bleeding, pain, and constipation (Table 4) (Harpole et al., 
1992; Smith, 1969). They are submucosally located and almost always diagnosed with 
endoscopic biopsies. Size is the major factor for metastasis. Tumors less than 1 cm in 
diameter has never been shown to have metastasized during a follow up of up to 25 years 
according to the Mayo Clinic experience. However, tumors more than 2 cm, which make up 
about 5%, behave aggressively. For patients with tumors between 1 cm and 2 cm, an 
individualized approach is appropriate considering age and comorbid conditions. 
6. Carcinoid syndrome 
The clinical presentation of the carcinoid tumors varies depending on localization, hormone 
production, and extent of disease. Midgut carcinoids often present with bowel obstruction 
or abdominal pain. Patients with rectal carcinoids often seek medical attention with 
bleeding. Lung carcinoids are found incidentally or they may secrete ACTH or CRH to 
present with Cushing's syndrome. Growth hormone-releasing hormone secreted by foregut 
carcinoids may cause acromegaly. Duodenal carcinoids may cause somatostatinoma 
syndrome. However, the most characteristic clinical feature of carcinoid tumors is carcinoid 
syndrome. 
Carcinoid syndrome, which is almost always seen when the tumor has metastasized to the 
liver, is the third most common mode of presentation of carcinoid tumors after bowel 
obstruction and abdominal pain. A small proportion of midgut carcinoids without liver 
metastasis can still present with carcinoid syndrome suggesting direct liberation of the 
causative agents into the systemic circulation. Flushing and diarrhea are the most common 
components of carcinoid syndrome, which are seen up to 89% of the patients during their 
course of the disease. Flushing is characterized by a sudden onset, deep red or violaceous 
erythema of the upper body often associated with a feeling of warmth. It is the prominent 
symptom in midgut carcinoids, which is thought to be due to catecholamine induced 
kallikrein release. In bronchial carcinoids, the flushing is usually prolonged sometimes 
hours or days giving rise to permanent dilatation of facial veins and telangiectasia. Gastric 
carcinoids may cause a characteristic flush that is reddish in color and pachy in distribution 
reminiscent of an urticarial reaction, which may be inhibited by histamine antagonists 
(Adamson et al., 1969). Other manifestations include asthma, edema, right heart vulvular 
lesions, the most common of which is tricuspid regurgitation, a loud sound of the pulmonic 
component of the 2nd heart sound, pellegra-like skin lesions, peptic ulcer, and arthralgia. 
Malignant carcinoid syndrome denotes patients with these manifestations combined with 
liver metastasis and elevated urinary 5-HIAA levels. Some patients may display only a few 
of the above signs. Usually, a full-blown carcinoid syndrome is seen in patients with 
extensive hepatic metastases. Some patients may have hepatic metastases with minimal 
symptoms and they generally look well. Ovarian and bronchial carcinoids may cause 
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carcinoid syndrome without documented liver metastasis. While patients with small 
intestinal and proximal colonic carcinoids produce carcinoid syndrome most commonly, it 
is less commonly seen in bronchial carcinoids and does not occur in rectal carcinoids 
(Harpole et al., 1992; Smith, 1969; Caldarola et al., 1964). Due to the vagueness of the 
symptoms or no symptoms at all, diagnosis is delayed approximately 2 to 3 years (Norheim 
et al., 1987). 
7. Diagnosis 
The diagnosis of a carcinoid tumor depends on the symptomatology of carcinoid syndrome 
or the presence of other symptoms such as abdominal discomfort. Nevertheless, 60% of the 
patients with gastrointestinal carcinoids found at surgery were asymptomatic in one study 
(Thompson et al., 1985). The histopathologic diagnosis is made using immunohistochemical 
techniques, namely antibodies directed against chromogranin A (CgA), synaptophysin, and 
NSE. In patients with carcinoid syndrome the diagnosis can be made measuring urinary 5-
HIAA levels. Levels of 15 to 60 mg/24 hours are compatible with midgut carcinoid tumors 
with 60 to 73% of sensitivity and 100% specificity. The most sensitive marker is plasma CgA, 
albeit not specific, since other neuroendocrine tumors can secrete this substance. Foregut 
carcinoids, on the other hand, may produce an atypical carcinoid syndrome with minimally 
elevated or normal urinary 5-HIAA level since they lack the enzyme L-amino-acid 
decarboxylase. The diagnosis of these tumors rely upon measurement of urinary metabolites 
of tryptophan such as 5-HTP or 5-HT. Patients should abstain from bananas, avocado, 
pineapple, walnuts, chocolate, and coffee; and avoid drugs such as chlorpromazine (Bertino 
& Cole, 1956) salicylates, and L-dopa at least 24 hours before the sample is presented to the 
lab (DeVita et al., 2011). 
8. Localization 
After the diagnosis has been made localization should be determined for the optimal 
management of the carcinoid tumor. Bronchial carcinoids are located in the airways of the 
central or middle third of the lung in 80% of cases. Chest x-ray, computed tomography (CT) 
or bronchoscopy is used to detect these tumors (Nessi et al., 1991). In plain radiography, 
they appear as a well-demarcated round or ovoid mass, often notched. Small tumors, which 
are often the case, are best detected by CT scanning. The mass may be visible within the 
bronchial lumina with an extraluminal component. In peripheral lesions, the mass is 
typically round or ovoid with a smooth or lobulated border. MRI is reserved for cases in 
which pulmonary carcinoid is suspected but cannot be visualized on CT. 
As midgut carcinoids are small tumors, they are sometimes detected by angiography or 
somatostatin-receptor scintigraphy (SRS) if not detected by barium enema, CT or MRI. 
Secondary features such as liver metastases and bowel obstruction are more often visualized 
than the primary tumor. Liver metastasis can be visualized by CT or MRI. Positron emission 
tomography (PET) using 11C-5-HTP is another localization modality with a high sensitivity 
(Orlefors et al., 1998; Sundin et al., 2004). Echocardiography should be performed in all 
patients with carcinoid syndrome to detect signs of carcinoid heart disease which is 
associated with poor survival.  
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Hindgut carcinoids are usually localized at endoscopy. They appear as solitary yellowish 
submucosal lesions. Endoscopic ultrasound may demonstrate invasion of the full rectal wall 
(stage T3) or adjacent structures (T4). 
In recent years, SRS or octreoscan and iodinated meta-iodobenzylguanidine (123I-MIBG) 
have been introduced to localize and stage the tumor. Five somatostatin receptors are 
currently recognized bound to varying degrees by the analogues 111In-octreotide, 111In-
lanreotide, and P829, a new technetium-99m (99mTc) analogue (Menda & Khan, 2002). 
Octreotide receptor imaging is most useful for the prediction of the success of octreotide 
therapy. If the scan is positive, then therapy will most likely be beneficial. It is also used 
peroperatively for perioperative tumor detection. Imaging with 123I-MIBG can also be 
performed for the prediction of therapy success with 131I-MIBG. The frequency of positive 
imaging in carcinoid tumors is 50-75% for 123I-MIBG and 67-96% for 111ln-octreotide. 123I-
MIBG scintigraphy, which is more widely available, appears to be more sensitive for 
sympatho-adrenomedullary tumors such as pheochromocytomas and paragangliomas, 
whereas 111ln-octreotide detects more tumors in all other neuroendocrine neoplasms. 
9. Management of carcinoid tumors 
Tumor reduction and symptomatic control are the mainstays of treatment of carcinoid 
tumors. When the tumor is localized, surgical resection the extent of which is determined 
primarily by the tumor size, is the treatment of choice. Symptomatic control includes 
lifestyle changes, dietary supplementation, and medical treatments directed to specific 
symptoms of carcinoid syndrome. Benign cases can respond to avoiding physical and 
emotional stress, alcohol, spicy food, and certain drugs. Supplemental niacin is 
recommended in patients whose symptoms are due to serotonin excess to prevent pellegra. 
Heart failure due to carcinoid heart disease requires drugs such as angiotensin-converting 
enzyme (ACE) inhibitors and diuretics. Diarrhea may respond to loperamide or 
diphenoxylate. Side effects of these drugs are the main limiting factor in controlling 
carcinoid syndrome. Therefore, more specific drugs have been developed, one of which is 
octreotide, a somatostatin analogue. 
9.1 Surgical palliation 
Patients suspected with intestinal obstruction must be relieved of their obstruction even if 
they have extensive liver metastases. Liver metastases can be resected without jeopardizing 
survival in select patients (Que et al., 1995; McEntee et al., 1990; & Dousset, 1996). Liver 
resection has been associated with improved 5 year survival rates in several series and is 
recommended in appropriate patients to attempt cure or to debulk metastatic disease 
(Sutton et al., 2003). Embolization of the hepatic artery is another option for liver disease. 
Liver transplantation for highly selected patients offers a five-year survival rate of 69% 
according to a French study (Le Treut et al., 1997). Mesenteric ischemia should promptly be 
recognized and the affected bowel segment resected. 
9.2 Somatostatin analogues 
Somatostatin analogues interact with cellular and transmembrane somatostatin receptors 
coupled with G proteins. Five subtypes have been defined. Subtypes 2, 3 and 5 are most 
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important and somatostatin analogues exert their action primarily by binding to subtype 2 
(Kubota et al., 1994). Activation results in inhibition of growth factor production and release 
as well as antiproliferative effects (Scarpignato & Pelosini, 2001; Buscail et al., 1995; 
Cordelier et al., 1997 & Cattaneo et al., 1996). Receptor subtype 3 mediates phosphotyrosine 
phosphatase dependent apoptosis during high dose therapy (3mg daily octreotide or 12 mg 
daily lanreotide) (Imam et al., 1997). Octreotide is the most widely available drug followed 
by lanreotide and vapreotide. Subcutaneous administration of these drugs can control the 
symptoms in most of the patients. The recommended dose of immediate release form of 
octreotide is 100 mcg 2 or 3 times a day. The dose should be titrated upwards according to 
the symptoms sometimes up to 3000 mcg a day in 3 to 7 days. Tolerance is a common caveat 
in long-term use. Long-acting, slow-release formulation of octreotide with 20 and 30 mg of 
doses (up to 60 mg) every month (every 2 weeks for lanreotide) has enabled patients to 
enjoy a more comfortable life in terms of controlling symptoms and reducing the number of 
injections. The immediate release formulation and the long-acting form should overlap at 
least 2 weeks to achieve maximal symptom control. Patients with breakthrough symptoms 
may benefit from subcutaneous administration of the immediate release formulation. 
Treatment should be continued life-long or until troublesome side effects develop. 
Somatostatin analogues improve symptoms in 88% of patients and in 72%, urinary 5-HIAA 
excretion decreases (Kvols et al., 1986). 
9.3 Chemotherapy 
Metastatic carcinoid tumors are indolent tumors and response to chemotherapeutics is 
generally poor. Classical midgut carcinoids do not show any response to chemotherapy. 
Since foregut carcinoids are more malignant than others, cytotoxic therapy can be 
attempted. Combinations include streptozotocin plus 5-fluorouracil, doxorubicin, cisplatin 
plus etoposide, and dacarbazine plus 5-fluorouracil (Moertel et al., 1991; Di Bartolomeo et 
al., 1995 & Bajetta et al., 1998). Somatostatin analogues can be combined with the above 
regimens. A recent study showed that chemotherapy naïve patients with metastatic 
pancreatic endocrine carcinomas had an exceptionally high and durable response rate with 
the combination of temezolamide and capecitabine (Strosberg et al., 2011).  
9.4 Immunotherapy 
Oberg and his coworkers have reported a study form Sweden that 42% of patients with 
carcinoid syndrome had a reduction of their urinary 5-HIAA levels when treated with low 
dose human leukocyte interferon and recombinant leukocyte interferon-a (Oberg et al., 
1986), but there was only 11% tumor regression rate. Mayo Clinic tried higher doses of 
interferon (Moertel et al., 1991) and objective tumor regression was 20% but it was not 
durable. Toxicity was the major drawback. Oberg has suggested the dose of interferon be 
titrated according to the patient's neutrophil count. 
9.5 Angiogenesis inhibitors 
As neuroendocrine tumors are highly vascular tumors bevacizumab, a monoclonal antibody 
targeting vascular endothelial growth factor (VEGF), was tested in advanced 
neuroendocrine tumors. This phase II study resulted in objective responses, reduction of 
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tumor blood flow, and longer PFS in patients with carcinoid than PEG interferon treatment 
(Yao, 2008). Sunitinib, another molecule inhibiting VEGF receptors, is approved by FDA for 
the treatment of advanced or unresectable progressive well-differentiated pancreatic 
neuroendocrine tumors based on the phase III study stating that it improves progression-
free survival, overall survival, and the objective response rate of these tumors as compared 
with placebo (Raymond et al., 2011).  
9.6 Mammalian target of rapamycin (mTOR) inhibitors 
Everolimus inhibits mTOR, an intracellular serine/threonine kinase that regulates multiple 
signaling pahways. It showed activity in advanced or unresectable low-grade or 
intermediate-grade pancreatic neuroendocrine tumors (Yao et al., 2011) and approved by 
FDA for the treatment of advanced, unresctable, or locally advanced pancreatic 
neuroendocrine tumors.  
9.7 Radiation therapy 
External irradiation has been used for the palliation of bone and brain metastases (Schupak 
& Wallner, 1991 & Kimmig, 1994). Radiolabeled MIBG has been the most widely studied 
agent. It showed a 30% response rate with 125I-MIBG or 131I-MIBG (Hoefnagel et al., 1987 
& Taal et al., 1996). In one study, investigators performed a retrospective review of 98 
patients with metastatic carcinoid who were treated at their institution with 131I-MIBG over 
a 15-year period. The median survival after treatment was 2.3 years. Patients who 
experienced a symptomatic response had improved survival. For the 56 patients who had 5-
HIAA levels monitored, the mean urine 5-HIAA levels decreased significantly after 131I-
MIBG treatment. Authors concluded that 131I-MIBG treatment could be recommended in 
select patients with metastatic carcinoid who progress despite optimal medical 
management. Improved survival was predicted best by symptomatic response to 131I-MIBG 
treatment, but not by hormone or radiographic response (Safford et al., 2004). 111ln-
octreotide is a somatostatin analogue-based tumor-targeted radioactive agent. It is most 
often used when imaging with 123I-MIBG fails to detect any tumor. When 111In-octreotide 
is avidly concentrated within the tumors, then radionuclide labeled octreotide can be 
administered. Studies with 90Y-labeled octreotide have shown that 83% of patients with 
carcinoid syndrome had a significant reduction in symptoms (Waldherr et al., 2001). 
9.8 Carcinoid heart disease 
In the pre-somatostatin era carcinoid heart disease used to occur in two thirds of patients 
with the carcinoid syndrome (Lundin et al., 1988). However, in the post-somatostatin era its 
incidence has dropped dramatically to 5% (Anthony et al., 2011). Right heart is affected most 
commonly. Tricuspid regurgitation, tricuspid stenosis, pulmonary regurgitation, and 
pulmonary stenosis may all occur. It is thought that these lesions are due to the secreted 
factors by the carcinoid cells of the liver metastases into the hepatic vein. Serotonin is 
blamed to be responsible for the cardiac lesions in carcinoid syndrome. However, its role in 
the development of cardiac lesions is poorly understood. Left heart is less often affected due 
to inactivation of serotonin by lung metabolism. Valvular replacement in patients with 
symptomatic heart disease proved unsuccessful due to the high perioperative mortality 
(Robiolio et al., 1995 & Connolly et al., 1995). 
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10. Prognosis 
Carcinoid syndrome represents an advanced disease and prognosis depends upon the site 
and extent of the disease. While in patients with localized disease the 5-year survival rate is 
approximately 65%, patients with advanced disease this figure drops to 36% (Godwin et al., 
1975). Female gender and young age at diagnosis are associated with a better prognosis. 
Presence of metastases, high CgA level, and high proliferation index (Ki-67) are indicators of 
a poor outcome. Once, carcinoid heart disease was a troublesome complication and a cause 
of early death. With modern diagnostic and therapeutic technics this is rarely seen today. 
Development of a secondary malignancy, namely an adenocarcinoma of the large intestine, 
is another cause of reduced survival in these patients (Godwin et al., 1975). Whether 
combined adenocarcinoma and carcinoid tumors are a composite tumor or collision tumors 
has been debated (Yamashina & Flinner, 1985).  
11. Conclusion 
Neuroendocrine tumors continue to evolve with regard to diagnosis, classification 
epidemiology and treatment possibilities. They also provide a challenging source of testing 
novel drugs as their molecular targets have now started to be recognized. 
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